Posted by Michael Wonder on 29 Mar 2017
New fast-acting mealtime insulin, Fiasp, now approved and available in Canada for the treatment of diabetes
27 March 2017 - Faster absorption of insulin key for Canadians living with diabetes.
Today, Novo Nordisk Canada announced that Fiasp (insulin aspart), a faster acting mealtime insulin, is now approved and available in Canada, giving Canadians living with diabetes a new treatment option for achieving optimal mealtime glucose control.
